Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019
Management will host a conference call at
The call may also be accessed by dialing 877-270-2148 (U.S.) or 412-902-6510 (international) and asking the operator to join the
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.
|
Investor contact: |
Media contact: |
Media contact (UK): |
|
Susan A. Noonan |
Silvia Taylor |
Julia Wilson |
|
S.A. Noonan Communications |
Vice President, Corporate Affairs |
JW Communications |
|
+1-212-966-3650 |
and Communications, Autolus |
+44 (0) 7818 430877 |
|
+1-240-801-3850 |
||
SOURCE